



Reference list

Biacore™ systems

Biophysical techniques

Review

Renaud, J.P. *et al.* Biophysics in drug discovery: impact, challenges and opportunities. *Nat Rev Drug Discov.* **10**, 679–98 (2016). doi: 10.1038/nrd.2016.123. <https://www.ncbi.nlm.nih.gov/pubmed/27516170>

Masson, J-F. Surface Plasmon Resonance Clinical Biosensors for Medical Diagnostics. *ACS Sens.* **2** (1), 16–30 (2017). doi: 10.1021/acssensors.6b00763. <https://www.ncbi.nlm.nih.gov/pubmed/28722437>

Antigen Binding

Usui, D. *et al.* Light-chain residue 95 is critical for antigen binding and multispecificity of monoclonal antibody G2. *Biochem Biophys Res Commun.* **490**(4), 1205–1209 (2017). doi: 10.1016/j.bbrc.2017.06.183. <https://www.ncbi.nlm.nih.gov/pubmed/28669727>

Henry, K.A. *et al.* A disulfide-stabilized human V_L single-domain antibody library is a source of soluble and highly thermostable binders. *Mol Immunol.* 190–196 (2017). doi: 10.1016/j.molimm.2017.07.006. <https://www.ncbi.nlm.nih.gov/pubmed/28820969>

Birch, J. *et al.* Effect of repeat unit structure and molecular mass of lactic acid bacteria hetero-exopolysaccharides on binding to milk proteins. *Carbohydr Polym.* **177**, 406–414 (2017). doi: 10.1016/j.carbpol.2017.08.055. <https://www.ncbi.nlm.nih.gov/pubmed/28962786>

Wang, W. *et al.* Glycan profiling of proteins using lectin binding by Surface Plasmon Resonance. *Anal Biochem.* **538**, 53–63 (2017). doi: 10.1016/j.ab.2017.09.014. <https://www.ncbi.nlm.nih.gov/pubmed/28947169>

Biotherapeutics

Review

Yang, D. *et al.* Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics. *Anal Biochem.* **508**, 78–96 (2016). doi: 10.1016/j.ab.2016.06.024. <https://www.ncbi.nlm.nih.gov/pubmed/27365220>

Federici, M. *et al.* Analytical lessons learned from selected therapeutic protein drug comparability studies. *Biologicals.* **41** (3), 131–47 (2013). doi: 10.1016/j.biologicals.2012.10.001. <https://www.ncbi.nlm.nih.gov/pubmed/23146362>

Shih H.H. Discovery Process for Antibody-Based Therapeutics (Chapter 2), in *Development of Antibody-Based Therapeutics* (Tabrizi, M.A. *et al.* eds.), Springer International Publishing AG, Germany, pp. 9–22 (2012). doi: 10.1007/978-1-4419-5955-3_2. <http://www.springer.com/la/book/9781441959539>

Willemsen-Seegers, N. *et al.* Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. *J Mol Biol.* **429** (4), 574–586 (2017). <https://www.sciencedirect.com/science/article/pii/S0022283616305587?via%3Dihub>

Antibody screening

Shen, Y. *et al.* Preparation and characterization of a high-affinity monoclonal antibody against human epididymisprotein-4. *Protein Expr Purif.* **141**, 44–51 (2018). doi: 10.1016/j.pep.2017.09.005. www.ncbi.nlm.nih.gov/pubmed/28928083

Vincent, K. J. and, Zurini, M. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. *Biotechnol J.* **7** (12), 1444–50 (2012). doi: 10.1002/biot.201200250. <https://www.ncbi.nlm.nih.gov/pubmed/23125076>

Hearty, S. *et al.* Measuring antibody-antigen binding kinetics using surface plasmon resonance. *Methods Mol Biol.* **907**, 411–42 (2012). doi: 10.1007/978-1-61779-974-7_24. <https://www.ncbi.nlm.nih.gov/pubmed/22907366>

Schräml, M. and von Proff, L. Temperature-dependent antibody kinetics as a tool in antibody lead selection. *Methods Mol Biol.* **901**, 183–94 (2012). doi: 10.1007/978-1-61779-931-0_12. <https://www.ncbi.nlm.nih.gov/pubmed/22723102>

Schräml, M. and Biehl, M. Kinetic screening in the antibody development process. *Methods Mol Biol.* **901**,171-81 (2012). doi: 10.1007/978-1-61779-931-0_11. <https://www.ncbi.nlm.nih.gov/pubmed/22723101>

Kamat, V. and Rafique, A. Extending the throughput of Biacore 4000 biosensor to accelerate kinetic analysis of antibody-antigen interaction. *Anal Biochem.* **530**, 75-86 (2017). doi: 10.1016/j.ab.2017.04.020. <https://www.ncbi.nlm.nih.gov/pubmed/28465032>

Katsamba, P.S. Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users. *Anal Biochem.* **352(2)**, 208-21 (2006). <https://www.ncbi.nlm.nih.gov/pubmed/16564019>

Usui, D. *et al.* Light-chain residue 95 is critical for antigen binding and multispecificity of monoclonal antibody G2. *Biochem Biophys Res Commun.* **490(4)**:1205-1209 (2017). doi: 10.1016/j.bbrc.2017.06.183. <https://www.ncbi.nlm.nih.gov/pubmed/28669727>

Novel antibody formats

Gassner, C. Development and validation of a novel SPR-based assay principle for bispecific molecules. *J Pharm Biomed Anal.* **102**, 144-9 ((2014). doi: 10.1016/j.jpba.2014.09.007. <https://www.ncbi.nlm.nih.gov/pubmed/25277666>

Stubenrauch, K. *et al.* An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab. *J Pharm Biomed Anal.* **102**, 459-67 (2015). doi: 10.1016/j.jpba.2014.10.005. <https://www.ncbi.nlm.nih.gov/pubmed/25459946>

Rauscher, A. *et al.* Influence of pegylation and hapten location at the surface of radiolabeled liposomes on tumour immunotargeting using bispecific antibody. *Nucl Med Biol.* **Suppl**, e66-74 (2014). doi: 10.1016/j.nucmedbio.2013.12.012. <https://www.ncbi.nlm.nih.gov/pubmed/24485990>

Castoldi, R. *et al.* Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. *Protein Eng Des Sel.* **25** (10):551-9 (2012). <https://www.ncbi.nlm.nih.gov/pubmed/22936109>

Bostrom, J. *et al.* High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. *PLoS One.* **6(4)**, e17887 (2011). doi: 10.1371/journal.pone.0017887. <https://www.ncbi.nlm.nih.gov/pubmed/21526167>

Meschendoerfer, W. *et al.* SPR-based assays enable the full functional analysis of bispecific molecules. *J Pharm Biomed Anal.* **132**, 141-147 (2017). doi: 10.1016/j.jpba.2016.09.028. <https://www.ncbi.nlm.nih.gov/pubmed/27721070>

Epitope analysis

Lin, J. C. *et al.* Six amino acid residues in a 1200 Å² interface mediate binding of factor VIII to an IgG4k inhibitory antibody. *PLoS One.* **10(1)**, e0116577 (2015). doi: 10.1371/journal.pone.0116577. <https://www.ncbi.nlm.nih.gov/pubmed/25615825>

Nguyen, P. C. *et al.* High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance. *Blood.* **123(17)**, 2732-9 (2014). doi: 10.1182/blood-2013-09-527275. <https://www.ncbi.nlm.nih.gov/pubmed/24591205>

Abdiche, Y.N. *et al.* Exploring blocking assays using Octet, ProteOn, and Biacore biosensors. *Anal Biochem.* **386(2)**, 172-80 (2009). doi: 10.1016/j.ab.2008.11.038. <https://www.ncbi.nlm.nih.gov/pubmed/19111520>

Abdiche, Y.N. *et al.* Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. *Protein Sci.* **17(8)**, 1326-35 (2008). doi: 10.1110/ps.035402.108. <https://www.ncbi.nlm.nih.gov/pubmed/18505735>

Abdiche, Y.N. *et al.* Antibodies Targeting Closely Adjacent or Minimally Overlapping Epitopes Can Displace One Another. *PLoS One.* **12(1)**, e0169535 (2017). doi: 10.1371/journal.pone.0169535. <https://www.ncbi.nlm.nih.gov/pubmed/28060885>

Comparison with ELISA

Heinrich, L. *et al.* Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity. *J Immunol Methods.* **352(1-2)**, 13-22 (2010). doi: 10.1016/j.jim.2009.10.002. <https://www.ncbi.nlm.nih.gov/pubmed/19854197>

FcγR – Review

Berkowitz, S. A. *et al.* Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. *Nat Rev Drug Discov.* **11(7)**, 527-40 (2012). doi: 10.1038/nrd3746. <https://www.ncbi.nlm.nih.gov/pubmed/22743980>

Jiang, X. R. *et al.* Advances in the assessment and control of the effector functions of therapeutic antibodies. *Nat Rev Drug Discov.* **10(2)**, 101-11 (2011). doi: 10.1038/nrd3365. <https://www.ncbi.nlm.nih.gov/pubmed/21283105>

van der Poel, C. E. *et al.* Functional characteristics of the high affinity IgG receptor, FcγRI. *J Immunol.* **186(5)**, 2699-704 (2011). doi: 10.4049/jimmunol.1003526. <https://www.ncbi.nlm.nih.gov/pubmed/21325219>

FcRn binding analysis

Sun, H. *et al.* Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease. *J Autoimmun.* **84**, 97-108 (2017). doi: 10.1016/j.jaut.2017.08.004. <https://www.ncbi.nlm.nih.gov/pubmed/28830653>

Abdiche, Y. N. *et al.* The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. *MAbs.* **7(2)**, 331-43 (2015). doi: 10.1080/19420862.2015.1008353. <https://www.ncbi.nlm.nih.gov/pubmed/25658443>

Stracke, J. *et al.* A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. *MAbs.* **6(5)**, 1229-42 (2014). doi: 10.4161/mabs.29601. <https://www.ncbi.nlm.nih.gov/pubmed/25517308>

Gurbaxani, B. *et al.* Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? *Mol Immunol.* **56(4)**, 660-74 (2013). doi: 10.1016/j.molimm.2013.05.008. <https://www.ncbi.nlm.nih.gov/pubmed/23917469>

Kelley, R. F. and Meng, Y. G. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function. *Methods Mol Biol.* **901**, 277-93 (2012). doi: 10.1007/978-1-61779-931-0_18. <https://www.ncbi.nlm.nih.gov/pubmed/22723108>

Leonard, P. *et al.* Rapid temperature-dependent antibody ranking using Biacore A100. *Anal Biochem.* **409(2)**, 290-2 (2011). doi: 10.1016/j.ab.2010.10.036. <https://www.ncbi.nlm.nih.gov/pubmed/21050836>

Steukers, M. *et al.* Rapid kinetic-based screening of human Fab fragments. *J Immunol Methods.* **310(1-2)**, 126-35 (2006). doi: 10.1016/j.jim.2006.01.002. <https://www.ncbi.nlm.nih.gov/pubmed/16481004>

Cooper, M. A. Label-free screening of bio-molecular interactions. *Anal Bioanal Chem.* **377(5)**, 834-42 (2003). doi: 10.1007/s00216-003-2111-y. <https://www.ncbi.nlm.nih.gov/pubmed/12904946>

FcRI binding analysis

Kiyoshi, M. Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. *Nat Commun.* **30;6**, 6866 (2015). doi: 10.1038/ncomms7866. <https://www.ncbi.nlm.nih.gov/pubmed/25925696>

FcγR – Fc structure and binding analysis

Wessels, U. *et al.* Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I. *Bioanalysis.* **8(20)**, 2135-45 (2016). doi: 10.4155/bio-2016-0182. <https://www.ncbi.nlm.nih.gov/pubmed/27582032>

Hayes, J. M. *et al.* Fc gamma receptor glycosylation modulates the binding of IgG glycoforms: a requirement for stable antibody interactions. *J Proteome Res.* **13(12)**, 5471-85 (2014). doi: 10.1021/pr500414q. <https://www.ncbi.nlm.nih.gov/pubmed/25345863>

Zeck, A. *et al.* Cell type-specific and site directed N-glycosylation pattern of FcγRIIIa. *J Proteome Res.* **10(7)**, 3031-9 (2011). doi: 10.1021/pr1012653. <https://www.ncbi.nlm.nih.gov/pubmed/21561106>

Visser, J. *et al.* Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. *BioDrugs.* **27(5)**, 495-507 (2013). doi: 10.1007/s40259-013-0036-3. <https://www.ncbi.nlm.nih.gov/pubmed/23649935>

Heider, K. H. *et al.* A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. *Blood.* **118(15)**, 4159-68 (2011). doi: 10.1182/blood-2011-04-351932. <https://www.ncbi.nlm.nih.gov/pubmed/21795744>

Hulse, J. and Cox, C. *In Vitro Functional Testing Methods for Monoclonal Antibodies.* (2013, June 1) Retrieved from <http://www.bioprocessintl.com/manufacturing/monoclonal-antibodies/in-vitro-functional-testing-methods-for-monoclonal-antibody-biosimilars-344341/>

Shibata-Koyama, M. *et al.* The N-linked oligosaccharide at Fc gamma RIIIA Asn-45: an inhibitory element for high Fc gamma RIIIA binding affinity to IgG glycoforms lacking core fucosylation. *Glycobiology.* **19(2)**, 126-34 (2009). doi: 10.1093/glycob/cwn110. <https://www.ncbi.nlm.nih.gov/pubmed/18952826>

Bruhns, P. *et al.* Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. *Blood.* **113(16)**, 3716-25 (2009). doi: 10.1182/blood-2008-09-179754. <https://www.ncbi.nlm.nih.gov/pubmed/19018092>

Ferrara, C. *et al.* The carbohydrate at FcγRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms. *J Biol Chem.* **281(8)**, 5032-6 (2006). doi: 10.1074/jbc.M510171200. <https://www.ncbi.nlm.nih.gov/pubmed/16330541>

Sondermann, P. *et al.* The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex. *Nature.* **406(6793)**, 267-73 (2000). doi: 10.1038/35018508 <https://www.ncbi.nlm.nih.gov/pubmed/10917521>

Radaev, S. *et al.* The structure of a human type III Fcγ receptor in complex with Fc. *J Biol Chem.* **276(19)**, 16469-77 (2001). doi: 10.1074/jbc.M100350200. <https://www.ncbi.nlm.nih.gov/pubmed/11297532>

Hayes, J. M. *et al.* Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab. *Mol Cell Proteomics.* **2017 16(10)**, 1770-1788 (2017). doi: 10.1074/mcp.M117.066944. <https://www.ncbi.nlm.nih.gov/pubmed/28576848>

Kinetics and PK

Moscetti, I. *et al.* Binding kinetics of mutant p53R175H with wild type p53 and p63: A Surface Plasmon Resonance and Atomic Force Spectroscopy study. *Biophys Chem.* **228**, 55-61 (2017). doi: 10.1016/j.bpc.2017.07.002. <https://www.ncbi.nlm.nih.gov/pubmed/28697449>

Igawa, T. *et al.* Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. *Nat Biotechnol.* **28(11)**, 1203-7 (2010). doi: 10.1038/nbt.1691. <https://www.ncbi.nlm.nih.gov/pubmed/20953198>

Fabini, E. and Danielson, U.H. Monitoring drug-serum protein interactions for early ADME prediction through Surface Plasmon Resonance technology. *J Pharm Biomed Anal.* **144**, 188-194 (2017). doi: 10.1016/j.jpba.2017.03.054. <https://www.ncbi.nlm.nih.gov/pubmed/28392047>

Schuetz, D.A. *et al.* Kinetics for Drug Discovery: an industry-driven effort to target drug residence time. *Drug Discov Today.* **22(6)** 896-911 (2017). doi: 10.1016/j.drudis.2017.02.002. <https://www.ncbi.nlm.nih.gov/pubmed/28412474>

Uitdehaag, J.C.M. *et al.* Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity. *J Mol Biol.* 2017 **429(14)**, 2211-2230. doi: 10.1016/j.jmb.2017.05.014. <https://www.ncbi.nlm.nih.gov/pubmed/28539250>

Reagent qualification

O'Hara, D.M. *et al.* Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. *AAPS J.* **14(2)**, 316-28 (2012). doi: 10.1208/s12248-012-9334-9. <https://www.ncbi.nlm.nih.gov/pubmed/22415613>

Staack, R.F. *et al.* Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. *Bioanalysis.* **3(5)**, 523-34 (2011). doi: 10.4155/bio.11.16. <https://www.ncbi.nlm.nih.gov/pubmed/21388265>

Late stage development and comparability

Rechlin, C. Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis. *ACS Chem. Biol.* **12(5)**, 1397-1415 (2017). <http://pubs.acs.org/doi/abs/10.1021/acscchembio.7b00062>

Karlsson, R. *et al.* Comparison of surface plasmon resonance binding curves for characterization of protein interactions and analysis of screening data. *Anal Biochem.* **502**, 53-63 (2016). doi: 10.1016/j.ab.2016.03.007. <https://www.ncbi.nlm.nih.gov/pubmed/27019155>

Pol, E. *et al.* Evaluation of calibration-free concentration analysis provided by Biacore™ systems. *Anal Biochem.* **510**, 88-97 (2016). doi: 10.1016/j.ab.2016.07.009. <https://www.ncbi.nlm.nih.gov/pubmed/27402174>

Federici, M. *et al.* Analytical lessons learned from selected therapeutic protein drug comparability studies. *Biologicals.* **41(3)**, 131-47 (2013). doi: 10.1016/j.biologicals.2012.10.001. <https://www.ncbi.nlm.nih.gov/pubmed/23146362>

Upton, R. *et al.* Orthogonal Assessment of Biotherapeutic Glycosylation: A Case Study Correlating N-Glycan Core Afucosylation of Herceptin with Mechanism of Action. *Anal Chem.* **88(20)**, 10259-10265 (2016). doi: 10.1021/acs.analchem.6b02994. <https://www.ncbi.nlm.nih.gov/pubmed/27620140>

Magenat, L. *et al.* Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®. *MAbs.* **9(1)**, 127-139 (2017). doi: 10.1080/19420862.2016.1259046. <https://www.ncbi.nlm.nih.gov/pubmed/27854156>

Hofmann, H.P. *et al.* Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel®). *Expert Opin Biol Ther.* **16(10)**, 1185-95 (2016). doi: 10.1080/14712598.2016.1217329. <https://www.ncbi.nlm.nih.gov/pubmed/27463856>

Potency, concentration determination and calibration-free concentration analysis

Karlsson, R., *et al.* Surrogate potency assays: Comparison of binding profiles complements dose response curves for unambiguous assessment of relative potencies. *J Pharm Anal.* [Online] (21 December 2017. Posting date.)

Pol, E., Roos, H. *et al.* Evaluation of calibration-free concentration analysis provided by Biacore™ systems. *Anal Biochem.* **510**, 88-97 (2016). doi: 10.1016/j.ab.2016.07.009. <https://www.ncbi.nlm.nih.gov/pubmed/27402174>

Visentin, J. *et al.* Calibration free concentration analysis by surface plasmon resonance in a capture mode. *Talanta.* **148**, 478-85 (2016). doi: 10.1016/j.talanta.2015.11.025. <https://www.ncbi.nlm.nih.gov/pubmed/26653475>

Frostell, Å. *Et al.* Nine surface plasmon resonance assays for specific protein quantitation during cell culture and process development. *Anal Biochem.* **477**, 1-9 (2015). doi: 10.1016/j.ab.2015.02.010. <https://www.ncbi.nlm.nih.gov/pubmed/25700863>

Karlsson, R. Biosensor binding data and its applicability to the determination of active concentration. *Biophys Rev.* 2016 **8(4)**, 347-358 (2016). doi: 10.1007/s12551-016-0219-5. <https://www.ncbi.nlm.nih.gov/pubmed/28510014>

Dorion-Thibaudeau, J. *et al.* Quantification and simultaneous evaluation of the bioactivity of antibody produced in CHO cell culture-The use of the ectodomain of FcγRI and surface plasmon resonance-based biosensor. *Mol Immunol.* 2017 **82**, 46-49 (2017). doi: 10.1016/j.molimm.2016.12.017. <https://www.ncbi.nlm.nih.gov/pubmed/28012362>

Membrane proteins

Immunogenicity

Shibata, H. *et al.* Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes. *J Immunol Methods*. **452**, 73-77 (2018). doi: 10.1016/j.jim.2017.09.009. <https://www.ncbi.nlm.nih.gov/pubmed/28970009>

Gibbs, E. *et al.* Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: a comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NAb. *Clin Immunol*. **157(1)**, 91-101 (2015). doi: 10.1016/j.clim.2014.12.005. <https://www.ncbi.nlm.nih.gov/pubmed/25543089>

Guidelines

Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product. U.S. Department of Health and human services/Food and drug Administration, (2014).

Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product, U.S. Department of Health and human services/Food and drug Administration, (2012).

Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product, U.S. Department of Health and human services/Food and drug Administration, (2012).

Structure function

Kling, A. *et al.* Antibiotics. Targeting DnaN for tuberculosis therapy using novel griselimycins. *Science*. **348(6239)**, 1106-12 (2015). doi: 10.1126/science.aaa4690. <https://www.ncbi.nlm.nih.gov/pubmed/26045430>

Müller, M. *et al.* c-di-AMP recognition by *Staphylococcus aureus* PstA. *FEBS Lett*. **589(1)**, 45-51 (2015). doi: 10.1016/j.febslet.2014.11.022. <https://www.ncbi.nlm.nih.gov/pubmed/25435171>

Rechlin, C. *et al.* Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis. *ACS Chem Biol*. **12(5)**, 1397-1415 (2017). doi: 10.1021/acscchembio.7b00062. <https://www.ncbi.nlm.nih.gov/pubmed/28287700>

Protein-DNA binding

Rollins, M.F. *et al.* Mechanism of foreign DNA recognition by a CRISPR RNA-guided surveillance complex from *Pseudomonas aeruginosa*. *Nucleic Acids Res*. **43(4)**, 2216-22 (2015). doi: 10.1093/nar/gkv094. <https://www.ncbi.nlm.nih.gov/pubmed/25662606>

Groothuizen, F.S. *et al.* Using stable MutS dimers and tetramers to quantitatively analyze DNA mismatch recognition and sliding clamp formation. *Nucleic Acids Res*. **41(17)**, 8166-81 (2013). doi: 10.1093/nar/gkt582. <https://www.ncbi.nlm.nih.gov/pubmed/23821665>

Review

Patching, S.G. Surface plasmon resonance spectroscopy for characterization of membrane protein-ligand interactions and its potential for drug discovery. *Biochim Biophys Acta*. **1838(1 Pt A)**, 43-55 (2014). doi: 10.1016/j.bbamem.2013.04.028. <https://www.ncbi.nlm.nih.gov/pubmed/23665295>

Chu, R. *et al.* Capture-stabilize approach for membrane protein SPR assays. *Sci Rep*. 2014 **4**, 7360. doi: 10.1038/srep07360. <https://www.ncbi.nlm.nih.gov/pubmed/25484112>

Nanodiscs

Bocquet, N. *et al.* Real-time monitoring of binding events on a thermostabilized human A2A receptor embedded in a lipid bilayer by surface plasmon resonance. *Biochim Biophys Acta*. **1848(5)**, 1224-33 (2015). doi: 10.1016/j.bbamem.2015.02.014. <https://www.ncbi.nlm.nih.gov/pubmed/25725488>

Adamson, R.J. and Watts, A. Kinetics of the early events of GPCR signaling. *FEBS Lett*. **588(24)**, 4701-7 (2014). doi: 10.1016/j.febslet.2014.10.043. <https://www.ncbi.nlm.nih.gov/pubmed/25447525>

Harding, P.J. *et al.* Direct analysis of a GPCR-agonist interaction by surface plasmon resonance. *Eur Biophys J*. 2006 **35(8)**, 709-12 (2006). doi: 10.1007/s00249-006-0070-x. <https://www.ncbi.nlm.nih.gov/pubmed/16708210>

Liposomes

Schillinger, A.S. *et al.* Two homologous neutrophil serine proteases bind to POPC vesicles with different affinities: When aromatic amino acids matter. *Biochim Biophys Acta*. **1838(12)**, 3191-202 (2014). doi: 10.1016/j.bbamem.2014.09.003. <https://www.ncbi.nlm.nih.gov/pubmed/25218402>

Membrane targets

Ogura, T. *et al.* Whole cell-based surface plasmon resonance measurement to assess binding of anti-TNF agents to transmembrane target. *Anal Biochem*. 2016 **508**, 73-7 (2016). doi: 10.1016/j.ab.2016.06.021. <https://www.ncbi.nlm.nih.gov/pubmed/27349512>

Vaccines

Review

Hearty, S. *et al.* Surface Plasmon Resonance for Vaccine Design and Efficacy Studies: Recent Applications and Future Trends. *Expert Rev Vaccines*. 2010 **9(6)**, 645-64 (2010). <https://www.ncbi.nlm.nih.gov/pubmed/20518719>

Van Regenmortel, M.H. Binding measurements as surrogate biological assays: surface plasmon resonance biosensors for characterizing vaccine components. *Dev Biol (Basel)*. 2000;**103**, 69-74 (2000). <https://www.ncbi.nlm.nih.gov/pubmed/11214255>

Research and vaccine development

Dai, L. *et al.* Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. *Cell Host Microbe*. 2016 **19(5)**, 696-704. doi: 10.1016/j.chom.2016.04.013. <https://www.ncbi.nlm.nih.gov/pubmed/27158114>

Pissani, F. *et al.* Improvement of antibody responses by HIV envelope DNA and protein co-immunization. *Vaccine*. **32(4)**, 507-13 (2014). doi: 10.1016/j.vaccine.2013.11.022. <https://www.ncbi.nlm.nih.gov/pubmed/24280279>

Lahoud, M.H. *et al.* DEC-205 is a cell surface receptor for CpG oligonucleotides. *Proc Natl Acad Sci U S A*. **109(40)**, 16270-5 (2012). doi: 10.1073/pnas.1208796109. <https://www.ncbi.nlm.nih.gov/pubmed/22988114>

Kovacs, J.M. *et al.* HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. *Proc Natl Acad Sci U S A*. **109(30)**, 12111-6 (2012). doi: 10.1073/pnas.1204533109. <https://www.ncbi.nlm.nih.gov/pubmed/22773820>

Malito, E. *et al.* Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. *Proc Natl Acad Sci U S A*. **109(14)**, 5229-34 (2012). doi: 10.1073/pnas.1201964109. <https://www.ncbi.nlm.nih.gov/pubmed/22431623>

Lee, H. *et al.* Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. *Antiviral Res*. **139** 49-58 (2017). doi: 10.1016/j.antiviral.2016.12.016. <https://www.ncbi.nlm.nih.gov/pubmed/28034741>

Process optimization, process control and product stability

Manin, C. *et al.* Method for the simultaneous assay of the different poliovirus types using surface plasmon resonance technology. *Vaccine*. **31(7)**, 1034-9. (2013). doi: 10.1016/j.vaccine.2012.12.046. <https://www.ncbi.nlm.nih.gov/pubmed/23277095>

Towne, V. *et al.* Pairwise antibody footprinting using surface plasmon resonance technology to characterize human papillomavirus type 16 virus-like particles with direct anti-HPV antibody immobilization. *J Immunol Methods*. 2013 **388(1-2)**, 1-7 (2013). doi: 10.1016/j.jim.2012.11.005. <https://www.ncbi.nlm.nih.gov/pubmed/23159495>

Mulder, A.M. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine. *PLoS One*. **7(4)**, e33235 (2012). doi: 10.1371/journal.pone.0033235. <https://www.ncbi.nlm.nih.gov/pubmed/22493667>

Westdijk, J. *et al.* Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. *Vaccine*. **29(18)**, 3390-7 (2011). doi: 10.1016/j.vaccine.2011.02.085. <https://www.ncbi.nlm.nih.gov/pubmed/21397718>

Zhao, Q. *et al.* In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization. *Vaccine*. **29(45)** 7936-41 (2011). doi: 10.1016/j.vaccine.2011.08.070. <https://www.ncbi.nlm.nih.gov/pubmed/21871939>

Small molecules and fragments

Review

Kaminski, T. *et al.* Harnessing the Versatility of Optical Biosensors for Target-Based Small-Molecule Drug Discovery. *ACS Sens.* **2(1)**, 10-15 (2017). doi: 10.1021/acssensors.6b00735. <https://www.ncbi.nlm.nih.gov/pubmed/28722441>

Renaud, J.P. *et al.* Biophysics in drug discovery: impact, challenges and opportunities. *Nat Rev Drug Discov.* **15(10)**, 679-98 (2016). doi: 10.1038/nrd.2016.123. <https://www.ncbi.nlm.nih.gov/pubmed/27516170>

Erlanson, D.A. *et al.* Twenty years on: the impact of fragments on drug discovery. *Nat Rev Drug Discov.* **15(9)**, 605-19 (2016). doi: 10.1038/nrd.2016.109. <https://www.ncbi.nlm.nih.gov/pubmed/27417849>

Andersson, K. *et al.* Label-free kinetic binding data as a decisive element in drug discovery. *Expert Opin Drug Discov.* **1(5)**, 439-46 (2006). doi: 10.1517/17460441.1.5.439. <https://www.ncbi.nlm.nih.gov/pubmed/23495944>

Small molecule screening

Huber, S. *et al.* SPR-based fragment screening with neurotensin receptor 1 generates novel small molecule ligands. *PLoS One.* 2017 **12(5)**, e0175842 (2017). doi: 10.1371/journal.pone.0175842. <https://www.ncbi.nlm.nih.gov/pubmed/28510609>

Structure kinetic relation

Uitdehaag J.C.M. *et al.* Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity. *J Mol Biol.* **429(14)**, (2017) <https://www.ncbi.nlm.nih.gov/pubmed/28539250>

Cramer, J. *et al.* Elucidating the Origin of Long Residence Time **Binding** for Inhibitors of the Metalloprotease Thermolysin. *ACS Chem Biol.* 2017 **12(1)**, 225-233 (2017). doi: 10.1021/acscchembio.6b00979. <https://www.ncbi.nlm.nih.gov/pubmed/27959500>

Krimmer, S.G. *et al.* Rational Design of Thermodynamic and Kinetic Binding Profiles by Optimizing Surface Water Networks Coating Protein-Bound Ligands. *J Med Chem.* 2016 **59(23)**, 10530-10548 (2016). doi: 10.1021/acs.jmedchem.6b00998. <https://www.ncbi.nlm.nih.gov/pubmed/27933956>

Heinrich, T. *et al.* Fragment-based discovery of new highly substituted 1H-pyrrolo[2,3-b]- and 3H-imidazolo[4,5-b]-pyridines as focal adhesion kinase inhibitors. *J Med Chem.* **56(3)**, 1160-70 (2013). doi: 10.1021/jm3016014. <https://www.ncbi.nlm.nih.gov/pubmed/23294348>

Danielson, U.H. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process. *Future Med Chem.* **1(8)**, 1399-414 (2009). doi: 10.4155/fmc.09.100. <https://www.ncbi.nlm.nih.gov/pubmed/21426056>

Andersson, K. and Hämäläinen, M. Replacing Affinity with Binding Kinetics in QSAR Studies Resolves Otherwise Confounded effects. *Journal of Chemometrics* **20**, 1-6 (2006). <http://onlinelibrary.wiley.com/doi/10.1002/cem.1010/full>

Markgren, P.O. *et al.* Relationships between structure and interaction kinetics for HIV-1 protease inhibitors. *J Med Chem.* **45(25)**, 5430-9 (2002). <https://www.ncbi.nlm.nih.gov/pubmed/12459011>

Willemsen-Seegers, N. *et al.* Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. *J Mol Biol.* 2017 **429(4)**, 574-586 (2017). doi: 10.1016/j.jmb.2016.12.019. <https://www.ncbi.nlm.nih.gov/pubmed/28043854>

Kinetic and biological function

Takeharu Ogura, *et al.* Whole cell-based surface plasmon resonance measurement to assess binding of anti-TNF agents to transmembrane target. *Anal. Biochem.* **508**, 73-77 (2001). <https://www.sciencedirect.com/science/article/pii/S0003269716301567?via%3Dihub>

Lei, H. *et al.* Identification of B. anthracis N(5)-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening. *Bioorg Med Chem.* 2016 **24(4)**, 596-605 (2016). doi: 10.1016/j.bmc.2015.12.029. <https://www.ncbi.nlm.nih.gov/pubmed/26740153>

Jones, A.M. *et al.* A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms. *Sci Rep.* **6**, 34701 (2016). doi: 10.1038/srep34701. <https://www.ncbi.nlm.nih.gov/pubmed/27708405>

Segala, E. *et al.* Biosensor-based affinities and binding kinetics of small molecule antagonists to the adenosine A(2A) receptor reconstituted in HDL like particles. *FEBS Lett.* 2015 **589(13)**, 1399-405 (2015). doi: 10.1016/j.febslet.2015.04.030. <https://www.ncbi.nlm.nih.gov/pubmed/25935416>

Dahl, G. and Akerud, T. Pharmacokinetics and the drug-target residence time concept. *Drug Discov Today.* 2013 **18(15-16)**, 697-707 (2013). doi: 10.1016/j.drudis.2013.02.010. <https://www.ncbi.nlm.nih.gov/pubmed/23500610>

Swinney, D.C. and Anthony, J. How were new medicines discovered? *Nat Rev Drug Discov.* **10(7)**, 507-19 (2011). doi: 10.1038/nrd3480. <https://www.ncbi.nlm.nih.gov/pubmed/21701501>

Tummino, P.J. and Copeland, R.A. Residence time of receptor-ligand complexes and its effect on biological function. *Biochemistry.* **47(20)**, 5481-92 (2008). doi: 10.1021/bi8002023. Erratum in: *Biochemistry.* **47(32)**, 8465 (2008). doi: 10.1021/bi8002023. <https://www.ncbi.nlm.nih.gov/pubmed/18412369>

Copeland, R.A. *et al.* Drug-target residence time and its implications for lead optimization. *Nat Rev Drug Discov.* **5(9)**, 730-9 (2006). Erratum in: *Nat Rev Drug Discov.* **6(3)**, 249 (2007). doi: 10.1038/nrd2082. <https://www.ncbi.nlm.nih.gov/pubmed/16888652>

Swinney, D.C. Biochemical mechanisms of drug action: what does it take for success? *Nat Rev Drug Discov.* **3(9)**, 801-8 (2004). doi: 10.1038/nrd1500. <https://www.ncbi.nlm.nih.gov/pubmed/15340390>

GE Healthcare Bio-Sciences AB
Björkgatan 30
751 84 Uppsala
Sweden

gelifesciences.com/biacore

GE, the GE Monogram, and Biacore are trademarks of General Electric Company.

© 2018 General Electric Company.

All goods and services are sold subject to the terms and conditions of sale of the company within GE Healthcare which supplies them.

A copy of these terms and conditions is available on request. Contact your local GE Healthcare representative for the most current information.

GE Healthcare UK Ltd., Amersham Place, Little Chalfont, Buckinghamshire, HP7 9NA, UK

GE Healthcare Europe GmbH, Munzinger Strasse 5, D-79111 Freiburg, Germany

GE Healthcare Bio-Sciences Corp., 100 Results Way, Marlborough, MA 01752, USA

HyClone Laboratories Inc., 925 W 1800 S, Logan, UT 84321, USA

GE Healthcare Japan Corp., Sanken Bldg., 3-25-1, Hyakunincho Shinjuku-ku, Tokyo 169-0073, Japan

For local office contact information, visit gelifesciences.com/contact.

KA1926230218RL